文献速递重症综合管理与镇静镇痛

COVID-19疫情对抗真菌药物消耗的影响:一项多中心回顾性分析

Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis.
PubMed 文献 · Crit Care · 2022-12-13
一句话结论COVID-19疫情期间医院及ICU伏立康唑和卡泊芬净消耗量增加,部分由COVID-19患者侵袭性真菌病发生率升高解释,作者认为亟需抗真菌药物管理措施。

该多中心回顾性研究纳入4个医疗点和14个ICU,比较COVID-19疫情前与疫情期间非COVID-19患者和COVID-19患者的抗真菌药物消耗及侵袭性真菌病发生率。2020年较2019年,全院和ICU伏立康唑消耗量分别增加40.3%和63.7%,ICU侵袭性曲霉病发生率增加46%;全院和ICU卡泊芬净消耗量分别增加34.9%和17.0%,侵袭性念珠菌病发生率分别增加20.0%和10.9%。作者认为抗真菌药物消耗增加部分由COVID-19患者侵袭性真菌病发生率升高解释,并强调亟需适当的抗真菌药物管理活动以控制消耗。

要点

  • 2020年较2019年,全院伏立康唑消耗量增加40.3%,ICU增加63.7%。
  • 2020年较2019年,ICU侵袭性曲霉病发生率增加46%。
  • 2020年较2019年,全院卡泊芬净消耗量增加34.9%,ICU增加17.0%。
  • 2020年较2019年,全院侵袭性念珠菌病发生率增加20.0%,ICU增加10.9%。
  • 作者认为抗真菌药物消耗增加部分由COVID-19患者侵袭性真菌病发生率升高解释,并呼吁开展抗真菌药物管理活动。

适用人群与场景

  • 4个医疗点和14个ICU的住院患者,包括非COVID-19患者和COVID-19患者,比较疫情前与疫情期间。

研究设计与关键结果

  • 多中心回顾性研究,纳入4个医疗点和14个ICU,描述疫情前与疫情期间非COVID-19患者和COVID-19患者的抗真菌药物消耗及侵袭性真菌病发生率。
  • 2020年较2019年,全院伏立康唑消耗量增加40.3%,ICU增加63.7%。
  • 2020年较2019年,ICU侵袭性曲霉病发生率增加46%。
  • 2020年较2019年,全院卡泊芬净消耗量增加34.9%,ICU增加17.0%。
  • 2020年较2019年,全院侵袭性念珠菌病发生率增加20.0%,ICU增加10.9%。
  • 作者认为抗真菌药物消耗增加部分由COVID-19患者侵袭性真菌病发生率升高解释。

证据类型、等级与局限

  • 多中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些结果引起对抗真菌药物消耗的担忧,亟需适当的抗真菌药物管理活动以控制消耗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In the context of COVID-19 pandemic, antifungal overuse may have occurred in our hospitals as it has been previously reported for antibacterials.

METHODS: To investigate the impact of COVID-19 on antifungal consumption, a multicenter retrospective study including four medical sites and 14 intensive care units (ICU) was performed. Antifungal consumption and incidences of invasive fungal diseases before and during COVID-19 pandemic, for non-COVID-19 patients and COVID-19 patients, were described.

RESULTS: An increase in voriconazole consumption was observed in 2020 compared with 2019 for both the whole hospital and the ICU (+ 40.3% and + 63.7%, respectively), whereas the incidence of invasive aspergillosis significantly increased in slightly lower proportions in the ICU (+ 46%). Caspofungin consumption also increased in 2020 compared to 2019 for both the whole hospital and the ICU (+ 34.9% and + 17.0%, respectively) with an increased incidence of invasive candidiasis in the whole hospital and the ICU but in lower proportions (+ 20.0% and + 10.9%, respectively).

CONCLUSIONS: We observed an increased consumption of antifungals including voriconazole and caspofungin in our hospital during the COVID-19 pandemic and explained in part by an increased incidence of invasive fungal diseases in COVID-19 patients. These results are of utmost importance as it raises concern about the urgent need for appropriate antifungal stewardship activities to control antifungal consumption.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bienvenu AL, Bestion A, Pradat P, et al. Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis. Crit Care. 2022. PMID: 36514110. doi:10.1186/s13054-022-04270-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。